Julien Taieb

Julien Taieb led the IDEA France consortium and contributed to the IDEA international collaboration that demonstrated non-inferiority of 3 versus 6 months of adjuvant FOLFOX or CAPOX for low-risk stage III colon cancer, enabling oxaliplatin dose reduction and neuropathy mitigation. His research addresses the optimal balance of adjuvant therapy efficacy and toxicity in CRC, including patient-reported outcomes. He leads a major digestive oncology clinical trials program in France and contributes to European CRC guidelines. Taieb is a leading voice in precision adjuvant therapy selection for colorectal cancer.